Description: <p><b>Recombinant TRAIL</b> - Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand</p>
<p><b>Recommended Abbreviation:</b> rTRAIL</p>
<p><b>Alternative Names:</b> Recombinant TRAIL, recombinant TNFSF10, Apo2L/TRAIL</p>
<p><b>Type:</b> Recombinant protein / biologic anticancer agent / death-receptor agonist</p>
<p><b>Function:</b> Recombinant TRAIL binds primarily to the death receptors DR4 (TNFRSF10A) and DR5 (TNFRSF10B), causing death-inducing signaling complex formation, caspase-8 activation, downstream caspase activation, and apoptosis. Many cancer cells are more sensitive to TRAIL-induced apoptosis than normal cells, although resistance is common.</p>
<p><b>Cancer:</b> ↑ TRAIL-induced death-receptor signaling is generally favorable because it promotes extrinsic apoptosis in susceptible cancer cells. Recombinant TRAIL and TRAIL-receptor agonists have shown substantial preclinical anticancer activity, although clinical efficacy has been limited by short circulating half-life, receptor biology, and intrinsic or acquired TRAIL resistance.</p>